+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019

  • ID: 4901272
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 555 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Science SA
  • Celon Pharma SA
  • ethris GmbH
  • Intech Biopharm Ltd
  • Novartis AG
  • Rhizen Pharmaceuticals SA
  • MORE
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 9, 37, 13, 2, 81, 18 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science SA
  • Celon Pharma SA
  • ethris GmbH
  • Intech Biopharm Ltd
  • Novartis AG
  • Rhizen Pharmaceuticals SA
  • MORE
Introduction
Report Coverage
Chronic Obstructive Pulmonary Disease (COPD) - Overview
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
AB Science SA
AB2 Bio Ltd
Adamis Pharmaceuticals Corp
Afimmune Biopharma Ltd
Aibios Co Ltd
AlgiPharma AS
Allinaire Therapeutics LLC
Amgen Inc
Angiocrine Bioscience Inc
apceth Biopharma GmbH
Apollo Therapeutics LLC
Aquilon Pharmaceuticals SA
Aridis Pharmaceuticals Inc
Ark Biosciences Inc
AstraZeneca Plc
AusBio Ltd
Avidin Ltd
Axolo Pharma Inc
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Bayer AG
BioMarck Pharmaceuticals Ltd
Boehringer Ingelheim International GmbH
C4X Discovery Holdings Plc
Celon Pharma SA
Chiesi Farmaceutici SpA
China Resources Pharmaceutical Group Ltd
Cipla Ltd
Circassia Pharmaceuticals Plc
Covenant Therapeutics LLC
CSL Ltd
Cureveda LLC
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Domainex Ltd
EmeraMed Ltd
EmphyCorp Inc
Emphymab Biotech LLC
Enterprise Therapeutics Ltd
EpiEndo Pharmaceuticals Ehf
Epitracker Inc
Errant Gene Therapeutics LLC
ethris GmbH
Evaxion Biotech ApS
Exotect LLC
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Future Medicine Co Ltd
Galapagos NV
GeneFrontier Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Grifols SA
iCeutica Inc
Icure Pharmaceutical Inc
InMed Pharmaceuticals Inc
Inmunotek SL
Insmed Inc
Intech Biopharm Ltd
INVENT Pharmaceuticals Inc
Invion Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
KBP BioSciences Co Ltd
Kither Biotech Srl
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Mariposa Health Ltd
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Metagone Biotech Inc
MetrioPharm AG
Naegis Pharmaceuticals Inc
NB Health Laboratory Co Ltd
Novabiotics Ltd
Novartis AG
Noveome Biotherapeutics Inc
Omnispirant Ltd
OncoArendi Therapeutics SA
Oncostellae SL
OPKO Health Inc
Orchid Pharma Ltd
Palo BioFarma SL
PharmaLundensis AB
Pharmaxis Ltd
Promedior Inc
Prous Institute for Biomedical Research SA
Pulmatrix Inc
Qu Biologics Inc
Quark Pharmaceuticals Inc
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Respiratorius AB
Rhizen Pharmaceuticals SA
Santhera Pharmaceuticals Holding AG
Silurian Pharmaceuticals Inc
Silver Valley Pharmaceutical Co Ltd
SolAeroMed Inc
sterna biologicals Gmbh & Co KG
Sulfateq BV
Sun Pharma Advanced Research Company Ltd
Symmune Therapeutics LLC
Synairgen Plc
Synovo GmbH
Syntrix Biosystems Inc
Taiho Pharmaceutical Co Ltd
TFF Pharmaceuticals Inc
TGV-Inhalonix Inc
Theratrophix LLC
Torrent Pharmaceuticals Ltd
Unity Biotechnology Inc
Verona Pharma Plc
Verra Therapeutics LLC
vTv Therapeutics Inc
Yungjin Pharm Co Ltd
Zai Lab Ltd
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apollo Therapeutics LLC, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquilon Pharmaceuticals SA, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ark Biosciences Inc, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AusBio Ltd, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Avidin Ltd, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H2 2019
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AB Science SA
  • AB2 Bio Ltd
  • Adamis Pharmaceuticals Corp
  • Afimmune Biopharma Ltd
  • Aibios Co Ltd
  • AlgiPharma AS
  • Allinaire Therapeutics LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • apceth Biopharma GmbH
  • Apollo Therapeutics LLC
  • Aquilon Pharmaceuticals SA
  • Aridis Pharmaceuticals Inc
  • Ark Biosciences Inc
  • AstraZeneca Plc
  • AusBio Ltd
  • Avidin Ltd
  • Axolo Pharma Inc
  • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
  • Bayer AG
  • BioMarck Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • C4X Discovery Holdings Plc
  • Celon Pharma SA
  • Chiesi Farmaceutici SpA
  • China Resources Pharmaceutical Group Ltd
  • Cipla Ltd
  • Circassia Pharmaceuticals Plc
  • Covenant Therapeutics LLC
  • CSL Ltd
  • Cureveda LLC
  • Cytokinetics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Denovo Biopharma LLC
  • Diffusion Pharmaceuticals Inc
  • Dimerix Ltd
  • Domainex Ltd
  • EmeraMed Ltd
  • EmphyCorp Inc
  • Emphymab Biotech LLC
  • Enterprise Therapeutics Ltd
  • EpiEndo Pharmaceuticals Ehf
  • Epitracker Inc
  • Errant Gene Therapeutics LLC
  • ethris GmbH
  • Evaxion Biotech ApS
  • Exotect LLC
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Future Medicine Co Ltd
  • Galapagos NV
  • GeneFrontier Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Grifols SA
  • iCeutica Inc
  • Icure Pharmaceutical Inc
  • InMed Pharmaceuticals Inc
  • Inmunotek SL
  • Insmed Inc
  • Intech Biopharm Ltd
  • INVENT Pharmaceuticals Inc
  • Invion Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • KBP BioSciences Co Ltd
  • Kither Biotech Srl
  • Koutif Therapeutics LLC
  • Kyowa Kirin Co Ltd
  • Liminal BioSciences Inc
  • LTT Bio-Pharma Co Ltd
  • Mariposa Health Ltd
  • Mereo Biopharma Group Plc
  • Meridigen Biotech Co Ltd
  • Metagone Biotech Inc
  • MetrioPharm AG
  • Naegis Pharmaceuticals Inc
  • NB Health Laboratory Co Ltd
  • Novabiotics Ltd
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Omnispirant Ltd
  • OncoArendi Therapeutics SA
  • Oncostellae SL
  • OPKO Health Inc
  • Orchid Pharma Ltd
  • Palo BioFarma SL
  • PharmaLundensis AB
  • Pharmaxis Ltd
  • Promedior Inc
  • Prous Institute for Biomedical Research SA
  • Pulmatrix Inc
  • Qu Biologics Inc
  • Quark Pharmaceuticals Inc
  • Re-Pharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Resolys Bio Inc
  • Respiratorius AB
  • Rhizen Pharmaceuticals SA
  • Santhera Pharmaceuticals Holding AG
  • Silurian Pharmaceuticals Inc
  • Silver Valley Pharmaceutical Co Ltd
  • SolAeroMed Inc
  • sterna biologicals Gmbh & Co KG
  • Sulfateq BV
  • Sun Pharma Advanced Research Company Ltd
  • Symmune Therapeutics LLC
  • Synairgen Plc
  • Synovo GmbH
  • Syntrix Biosystems Inc
  • Taiho Pharmaceutical Co Ltd
  • TFF Pharmaceuticals Inc
  • TGV-Inhalonix Inc
  • Theratrophix LLC
  • Torrent Pharmaceuticals Ltd
  • Unity Biotechnology Inc
  • Verona Pharma Plc
  • Verra Therapeutics LLC
  • vTv Therapeutics Inc
  • Yungjin Pharm Co Ltd
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
Adroll
adroll